In clinical, palbociclib in combination with letorzole (aromatase inhibitor) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with ER-positive and HER2-negative advanced breast cancer [8, 9]. Here, ESR1 is linked to breast cancer.